Keryx Biopharmaceuticals Inc. announced appointment of two industry leaders to Keryx's board of directors, which increases the size of the company's board to 10 members. On March 31, 2016, Steven C. Gilman, Ph.D., and Michael Rogers were elected as independent directors to Keryx's board of directors, effective immediately. Dr. Gilman brings broad scientific and development expertise to Keryx's board having led or built several successful R&D organizations; he served most recently, for seven years, as chief scientific officer at Cubist Pharmaceuticals until its acquisition by Merck & Co.

Mr. Rogers has been the chief financial officer of Acorda Therapeutics since October 2013 and brings to Keryx valuable experience from his two decades of financial leadership in the biotech industry. Four current board members, Michael Tarnok, Jack Kaye, Senator Wyche Fowler, Jr. and Joseph Feczko, M.D. will not seek re-election to the company's Board when their terms expire at Keryx's 2016 Annual Meeting in May.